Compare Cassava Sciences Inc (FLNA) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Williams-Sonoma, Inc. — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while Williams-Sonoma, Inc. trades at $242.65 (market cap $28.15B). The key difference: Williams-Sonoma, Inc. is far larger — about 714.5× Cassava Sciences Inc's market cap, and Williams-Sonoma, Inc. pays a 1.27% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Williams-Sonoma, Inc. for 59 Days on average.
| FLNA | WSM | |
|---|---|---|
Market Cap | $39.40M | $28.15B |
Volume | 759,018 | 1,351,262 |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $251.81 |
52-Week Low | $0.68 | $168.64 |
Typical Hold Time | 37 Days | 59 Days |
Enterprise Value | -$43.28M | $28.65B |
Dividend Yield | — | 1.27% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Williams-Sonoma (WSM) trades at $240.46, down 0.74% on the day, with a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $2.10 surpassing expectations. Revenue for 2025 was $7.71 billion, with a robust net income margin of 14.73% and high return on equity of 54.96%. Recent news highlights market share gains and AI integration driving growth.
The outlook remains positive with a consensus price target of $246.31, suggesting moderate upside. Key opportunities include sustained margin strength and digital initiatives, while risks involve housing market sensitivity and competitive pressures. Institutional sentiment is mixed with 32% buy ratings, but recent insider selling by the CFO warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
